About Veeva Systems Inc. Class A Common Stock (VEEV)
Veeva Systems Inc is a leading provider of cloud-based software solutions tailored specifically for the global life sciences industry. The company offers a range of products designed to streamline and enhance various aspects of the pharmaceutical and biotech sectors, including research and development, regulatory compliance, and commercial operations. By leveraging advanced technology and data analytics, Veeva enables life sciences organizations to improve their efficiency, accelerate drug development processes, and ensure adherence to regulatory standards, ultimately contributing to better patient outcomes and innovation in healthcare. Read More
Veeva Systems currently trades at $238.50 per share and has shown little upside over the past six months, posting a middling return of 1.5%. However, the stock is beating the S&P 500’s 6.2% decline during that period.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
VEEVA SYSTEMS INC-CLASS A was identified as an affordable growth stock. NYSE:VEEV is showing great growth, but also scores well on profitability. At the same time it seems to be priced reasonably.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Veeva Systems (NYSE:VEEV) and the best and worst performers in the vertical software industry.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the vertical software industry, including nCino (NASDAQ:NCNO) and its peers.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the vertical software industry, including Upstart (NASDAQ:UPST) and its peers.
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Expensive stocks often command premium valuations because the market thinks their business models are exceptional.
However, the downside is that high expectations are already baked into their prices, leaving little room for error if they stumble even slightly.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors.
However, their sheer size makes it more challenging to maintain high growth rates as they’ve already captured significant portions of their markets.
Shares of healthcare software provider Veeva Systems (NASDAQ:VEEV)
jumped 9.9% in the afternoon session after the company reported impressive fourth quarter (fiscal 2025) results which beat analysts' revenue and adjusted operating profit expectations. Notably, subscription services revenue, making up the bulk of total revenue, rose 17% year over year. This growth was driven by expanding adoption of Veeva's cloud-based solutions across both R&D and commercial segments, reflecting continued demand from life sciences companies.
Looking ahead, while full-year revenue guidance was just in line with Wall Street's estimates, full-year operating profit guidance was above. Overall, this was a solid quarter.
